10-K: Microbot Medical's 10-K Filing Reveals Ongoing Losses, Focus on LIBERTY System, and Recent Capital Raises

Microbot Medical's 10-K filing highlights the company's continued operating losses, its strategic focus on the LIBERTY Endovascular Robotic Surgical System, and recent capital raising activities to support its operations.

Summary

• Microbot Medical Inc. has filed its 10-K report, detailing its business, financial condition, and future outlook.
• The company specializes in developing robotic endoluminal surgery devices, with a primary focus on the LIBERTY Endovascular Robotic Surgical System.
• Microbot has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future.
• The company is awaiting potential FDA clearance of its 510(k) application for the LIBERTY system, anticipating commercialization activities to commence thereafter.
• Microbot submitted an IDE application with the U.S. Food and Drug Administration, in order to commence its pivotal clinical trial in humans.
• The company received ISO 13485:2016 certification for its quality management system.
• Microbot has recently commenced the establishment of a sales, marketing and product distribution infrastructure for the LIBERTY Endovascular Robotic Surgical System.
• The company has raised approximately $30.6 million through various offerings subsequent to December 31, 2024.
• Microbot's research and development efforts have been financed in part through Israeli Innovation Authority royalty bearing grants totaling approximately $1.9 million through December 31, 2024.
• The company is subject to extensive regulations by the FDA and other international regulatory bodies.
• Microbot's operations in Israel are subject to political, economic, and military risks, which have been exacerbated by the recent military actions and operations.
• The company has 21 employees as of March 24, 2025, and is commencing hiring a commercialization and sales team.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the progress with the LIBERTY system and recent capital raises, the ongoing losses and risks associated with regulatory approvals and market competition temper the overall sentiment.

Positives

• The company anticipates FDA marketing clearance for the LIBERTY system during the second quarter of 2025.
• Microbot expects CE Mark approval in the second half of 2026, allowing them to market the LIBERTY system in Europe.
• The company has raised approximately $30.6 million through various offerings subsequent to December 31, 2024.
• Microbot received ISO 13485:2016 certification for its quality management system.
• The company submitted an IDE application with the U.S. Food and Drug Administration, in order to commence its pivotal clinical trial in humans.

Negatives

• Microbot has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future.
• The company has a limited operating history outside of being a research and development-stage company.
• Microbot's operations in Israel are subject to political, economic, and military risks, which have been exacerbated by the recent military actions and operations.

Risks

• Microbot may not be able to raise additional capital when needed, potentially forcing delays or reductions in product development.
• Unsuccessful studies or trials relating to product candidates could have a material adverse effect on the company's prospects.
• The company's business depends heavily on the success of the LIBERTY Endovascular Robotic Surgical System.
• Microbot may not meet its development and commercialization objectives in a timely manner or at all.
• The company's ability to expand its technology platforms for other uses may be limited.
• Microbot may be subject to penalties and may be precluded from marketing its product candidates if it fails to comply with extensive governmental regulations.
• If Microbot fails to retain certain of its key personnel and attract and retain additional qualified personnel, Microbot might not be able to pursue its growth strategy effectively.
• Microbot operations in international markets involve inherent risks that Microbot may not be able to control.
• Intellectual property litigation and infringement claims could cause Microbot to incur significant expenses or prevent Microbot from selling certain of its product candidates.
• Existing and historical risks relating to our operations in Israel are being exacerbated by the current military actions and operations, and related activities, that commenced with the surprise attack on the State of Israel on October 7, 2023.

Future Outlook

Microbot anticipates FDA marketing clearance for the LIBERTY system during the second quarter of 2025 and CE Mark approval in the second half of 2026. The company expects to continue investing in research and development and to seek additional funding through equity offerings or other means.

Management Comments

• Microbot is primarily focused on leveraging our robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients.
• Microbot believes that with the LIBERTY Endovascular Robotic Surgical System, coupled with its own NovaCross products and other off-the-shelf products, it is well-positioned to deliver a value-added endovascular robotic system, with a focus on improving the ease and access and enhancing the safety of endovascular interventions.

Industry Context

The document notes that the global Minimally Invasive Surgery (MIS) market is expected to grow significantly, and the U.S. market growth in endoluminal robotic surgery is projected to be 15-25% by 2025. This highlights the potential market opportunity for Microbot's LIBERTY system.

Comparison to Industry Standards

• The main competitor to the LIBERTY Endovascular Robotic Surgical System is the CorPath GRX vascular robotics system by Corindus Vascular Robotics, a Siemens Healthineers company.
• Another competitor is R-One+ by Robocath (CE Marked, NMPA, South Africa for PCI only), and we believe there are many other competitors in the endovascular robotics space.
• We also expect that we could be competing with other technologies that are in different stages of development, including preclinical, clinical and without CE/FDA approvals, such as LN Robotics (approved in Korea for coronary interventions) Nanoflex Robotics, UAB Inovatyvi medicina and Endoways, of which additional competitive data will be required to better determine their respective positioning in the competitive landscape.

Legal Proceedings

• The Company was named as the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., (the Plaintiffs), against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020) (the Lawsuit).
• On April 28, 2019, the Company brought an action against Alliance Investment Management, Ltd. (Alliance), later amended to add Joseph Mona (Mona) as a defendant, in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934 (the Exchange Act), to compel Alliance and/or Mona to disgorge short swing profits realized from purchases and sales of the Companys securities within a period of less than six months.

Stakeholder Impact

• Shareholders: Dilution from potential future equity offerings.
• Employees: Potential impact on job security and compensation due to financial performance.
• Customers: Potential for innovative surgical solutions if the LIBERTY system is successfully commercialized.
• Suppliers: Continued business relationships for manufacturing and development.
• Creditors: Ability to repay debts dependent on future financial performance and capital raising.

Next Steps

• Continue to refine existing product candidates and develop additional surgical robotic solutions.
• Establish and leverage relationships with key institutions and leading clinicians.
• Continuously invest in research and development.
• Explore partnerships for the introduction of Microbots products.
• Seek additional IP and technologies to complement and strengthen Microbots current IP portfolio.

Key Dates

Keywords

LIBERTY Endovascular Robotic Surgical System, Microbot Medical, Medical devices, Robotics, FDA, Clinical trials, Capital raise, ISO 13485, Israel, Innovation